Navigation Links
New molecular insight into amboebic dysentery
Date:6/14/2008

In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.

"New drug targets are needed for amebiasis as current treatments have associated toxicities and drug resistance is a concern." said Dr. Upinder Singh, a clinician at Stanford University and co-author of the study.

E. histolytica is a single-celled intestinal parasite that infects the lower GI tract, causing amoebiasis, and can invade the intestinal wall and spread to the bloodstream, causing potentially fatal amoebic liver abscesses. The parasite is transmitted through fecally contaminated food or water, and is a major public health threat in the developing world.

Dr. Urban and colleagues uncovered new insight into the activity of E. histolytica's single rhomboid protease protein, EhROM1, which suggests that it helps the parasite evade the host's immune response. In order to escape immune detection, E. histolytica trophozoites concentrate immune system-eliciting surface proteins towards the rear of the cell and then expel them. Dr. Urban's team discovered that EhROM1 processes surface lectin proteins, and collaborators at Stanford University found that it re-localizes posteriorly during lectin shedding.

These findings suggest that EhROM1 facilitates lectin shedding and host immune system evasion by this pathogenic parasite. Dr. Urban is excited by the new findings, since "Enzymes have served as particularly successful drug targets in the past, so it's exciting to discover an ameba rhomboid enzyme with similar properties as a malaria rhomboid. We're hopeful that with additional work, we will be able to develop rhomboid inhibitors and evaluate if they could be applied as a more general anti-parasitic strategy in the future."


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
4. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
5. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
6. Research reveals molecular fingerprint of cocaine addiction
7. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
8. Study identifies molecular response of cartilage to injury
9. Molecular change may reveal risk of leukemia relapse
10. Study Details New Molecular Approach to Preventing Alzheimers
11. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... (BIAA) is collaborating with a New England student to educate the public on ... acclaim in 2016 for launching the first-ever National Concussion Awareness Day. , Brooke ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... recently launched community enrichment program. Partnering once again with Boys & Girls Clubs ... to help find the area’s very own American Idol. With all proceeds benefitting ...
(Date:8/16/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, awarding him ... who is in his third year at the University of California, Los Angeles majoring ...
(Date:8/16/2017)... ... 2017 , ... Melbourne’s reign as the world’s most liveable city has been ... Liveability Index. , The Index surveys 140 of the world’s cities and Melbourne has ... consistently come in the top three of the index. So what is it that ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company ... fourth consecutive year. With 197% revenue growth over the past three years, ... growing companies. , Previous honors include ranking 86th on the Inc. 500 ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach Cancer ... on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura ...
Breaking Medicine Technology: